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Interleukin-6 (IL-6) is an important modulator of inﬂammation and immunity whose dysregulation is associ-
ated with a number of disease states. There is evidence of signiﬁcant heritability in inter-individual variation
in IL6 gene expression but the genetic variants responsible for this remain to be deﬁned. We adopted a com-
bined approach of mapping protein and expression quantitative trait loci in peripheral blood mononuclear
cells using high-density single-nucleotide polymorphism (SNP) typing for 2000 loci implicated in cardio-
vascular, metabolic and inﬂammatory syndromes to show that common SNP markers and haplotypes of
LEP (encoding leptin) associate with a 1.7- to 2-fold higher level of lipopolysaccharide (LPS)-induced IL-6
expression. We subsequently demonstrate that basal leptin expression signiﬁcantly correlates with LPS-
induced IL-6 expression and that the same variants at LEP which associate with IL-6 expression are also
major determinants of leptin expression in these cells. We ﬁnd that variation involving two other genomic
regions, CAPNS1 (encoding calpain small subunit 1) and ALOX15 (encoding arachidonate 15-lipoxygenase),
show signiﬁcant association with IL-6 expression. Although this may be a subset of all such trans-acting
effects, we ﬁnd that the same ALOX15 variants are associated with induced expression of tumour necrosis
factor and IL-1beta consistent with a broader role in acute inﬂammation for ALOX15. This study provides evi-
dence of novel genetic determinants of IL-6 production with implications for understanding susceptibility to
inﬂammatory disease processes and insight into cross talk between metabolic and inﬂammatory pathways. It
also provides proof of concept for use of an integrated expression phenotype mapping approach.
INTRODUCTION
Interleukin-6 (IL-6) is a pleiotropic cytokine that plays criti-
cal roles in both innate and adaptive immunity and is vital in
the transition from an acute to a sustained inﬂammatory
response. Dysregulation of IL-6 signalling is implicated in
many disease processes characterized by chronic inﬂam-
mation and autoimmunity, including atherosclerosis, sepsis,
arthritis, inﬂammatory bowel disease and oncogenesis
together with dysfunctional metabolic states such as
obesity and hyperinsulinaemia (1). The importance of IL-6
in autoimmunity has recently been highlighted by the dem-
onstration that, in tandem with TGF-beta, IL-6 is vital to
the establishment of pro-autoimmunity T(H)17 lineage
T-cells and its continued presence inhibits the emergence
of their regulatory counterparts, T(reg) cells (2). Although
most cell types are capable of synthesizing IL-6, the majority
of circulating IL-6 in the acute inﬂammatory response is pro-
duced by macrophages and monocytes following Toll-like
receptor stimulation.
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vidual levels of expression of IL6 with twin studies demon-
strating signiﬁcant heritability, estimated at between 57 and
61% for ex vivo IL-6 production following endotoxin or
mitogen stimulation (3,4). To date attention has focused on
DNA sequence variation at the IL6 locus with evidence that
speciﬁc single-nucleotide polymorphisms (SNPs) in the IL6
promoter region are important determinants of gene
expression. This was based on reporter gene analysis and
association with IL-6 production in healthy individuals and
disease states and remains incompletely understood (5–9). It
is probable that determinants of the magnitude of IL-6
response are inﬂuenced by diversity at other genomic loci,
none of which have yet been resolved.
Mapping gene expression quantitative trait loci (eQTLs) at
the RNA level has proved a powerful approach to deﬁne puta-
tive functional genetic variants (10), while a recent report
identiﬁed protein QTLs (pQTLs) which may be of more rel-
evance to physiological or disease states (11). Resolution of
functionally important regulatory variants requires context-
speciﬁc effects to be considered. To date, the majority of pub-
lished studies in human subjects seeking to associate levels of
gene expression with SNP diversity have relied upon the use
of transformed lymphoblastoid cell lines (12–14) or more
recently have analysed basal levels of expression in blood or
serum (11,15,16). It is likely that many regulatory polymorph-
isms determining cytokine responses will only become appar-
ent upon stimulation of an immune response and that accurate
assessment of functional studies will depend upon the use of
appropriate cell types.
We aimed to deﬁne common SNPs associated with IL-6
production in peripheral blood mononuclear cells (PBMCs)
from healthy volunteers upon exposure to lipopolysaccharide
(LPS) which signals through Toll-like receptor-4. We
adopted an integrated expression phenotype mapping
approach which analysed both pQTLs and eQTLs using a
panel of SNP markers informative for gene loci implicated
in immune and inﬂammatory responses, and with suscepti-
bility to cardiovascular disease (17). This allowed us to
resolve speciﬁc SNPs and haplotypes in LEP, ALOX15 and
CAPNS1 associated with induced IL-6 expression.
RESULTS
Mapping common SNP markers associated
with IL-6 expression
We ﬁrst sought to establish pQTLs for IL-6 expression by ana-
lysing PBMCs from 96 healthy volunteers in either the resting
state or after induction with LPS. IL-6 production was strongly
induced by LPS at 2 ng/ml, from median basal levels of
0.056 ng/ml to a mean of 11.0 ng/ml after 6 h, with signiﬁcant
inter-individual variation observed. Levels of induced IL-6
expression within individuals was reproducible over time for
ﬁve healthy volunteers investigated on three separate
occasions, on average three weeks apart. A linear regression
model showed that when considered as categorical variables
in a forward stepwise manner using likelihood ratio testing,
the day of testing was not signiﬁcant (P . 0.05); however,
the subjects were signiﬁcantly associated with levels of IL-6
(P ¼ 0.0029), consistent with published data showing reprodu-
cibility of individual serum levels of IL-6 over time (18). For
the QTL analysis in the full panel of 96 volunteers, three repli-
cate stimulation assays were performed for a given individual
on a particular day, and the mean value used in subsequent
analyses.
We genotyped the volunteers for a panel of 45 237 SNPs
using the Illumina HumanCVD v1 beadchip which includes
high-density coverage of 2000 genes implicated in
immune and inﬂammatory responses with speciﬁc relevance
to vascular pathology, metabolic disorders and inﬂammatory
disease states (17). The high density of SNPs on this array
increases the probability of capturing functionally relevant
polymorphisms within the loci covered on this chip. We
found that 26 SNP markers at 17 genomic loci were associated
with IL-6 production at the protein level (P , 10
24), notably
involving the ALOX15, CAPNS1 and LEP genes at chromo-
some 17p13.3, 19q13.12 and 7q31.3, respectively (Fig. 1, Sup-
plementary Material, Fig. S1). When we compared these
results with IL-6 protein production at 6 h in response to a
higher dose of LPS stimulation (20 ng/ml), we saw high con-
cordance between the data sets with SNPs in ALOX15,
CAPNS1 and LEP being the most signiﬁcant hits of associ-
ation found shared between the two phenotypes (Fig. 1). We
then complemented this analysis by mapping eQTL based on
IL6 expression at the RNA level in response to LPS stimu-
lation. We found that the same SNP markers at ALOX15,
CAPNS1 and LEP were associated with IL6 expression,
being the only SNP markers consistently associated across
the phenotypes (Fig. 1, Supplementary Material, Fig. S1 and
Table S1). For the cohort of volunteers, levels of IL-6
protein and IL6 RNA were seen to be strongly correlated (Sup-
plementary Material, Fig. S2).
Cis- and trans-associations at LEP
The observed association of IL-6 expression with common
SNP markers at or near the LEP gene is of particular biologi-
cal interest given the evidence that leptin can play an impor-
tant immunomodulatory role, and speciﬁcally published data
showing that leptin can both directly activate and augment
IL-6 production by PBMCs induced with LPS (19–22). We
successfully genotyped 52 SNPs within a 25 kb region span-
ning LEP of which 16 SNPs were informative with a minor
allele frequency (MAF) of greater than 5%. Several common
SNP markers showed association with basal and induced
IL-6 expression phenotypes at this locus, notably rs4731427
(c.29þ3030T.C) (Fig. 2). Individuals possessing a copy of
the minor C allele had a 7-fold higher level of basal IL6
expression compared with those without (Fig. 3) (Mann–
Whitney test two-tailed P ¼ 0.003), while following LPS
induction (2 ng/ml) a 2.3-fold increase in IL6 expression was
seen at the RNA level. This was reproduced at the protein
level with a 1.7- or 2.0-fold higher level of IL-6 expression
(2 or 20 ng/ml LPS, respectively) (P , 0.0001 on unpaired
t-test, two-tailed, for either phenotype) (Fig. 3).
These results are consistent with the hypothesis that
differences in levels of expression of leptin modulate IL-6
responsiveness. We proceeded to analyse basal expression
of leptin in our cohort of healthy volunteers and found
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IL-6 (Supplementary Material, Fig. S2). Strikingly, when
we analysed leptin expression as a quantitative trait using
the panel of 45 237 SNPs, we found strong evidence of
association involving the same common SNP markers at
the LEP locus which had been associated with higher
induced IL-6 expression (Fig. 2). Possession of a copy of
the rarer C allele of rs4731427 associated with IL-6
expression phenotypes was associated with a 5.5-fold
higher LEP expression (Mann–Whitney test two-tailed
P ¼ 0.0045) (Fig. 3).
We found evidence of substantial linkage disequilibrium
(LD) across the LEP gene with a very low recombination
rate (Fig. 2) and we proceeded to analyse gene expression in
terms of the haplotypic structure at this locus for individuals
of Caucasian ancestry (Fig. 4). This deﬁned six haplotypes
and showed that for IL-6 and leptin expression phenotypes,
haplotype LEP4 was most strongly associated (Fig. 4). This
Figure 1. LPS-induced IL-6 transcript and protein expression phenotype mapping. (A) eQTL/pQTL analysis showing concordance of SNP associations for IL-6
expression phenotypes (unadjusted P-values less than 10
24) for rs11568131, rs17882574 and rs4731427 with rank order of association indicated. (B) Unadjusted
P-values for SNP associations together with empirical P-values derived from permutation analysis with population correction.
722 Human Molecular Genetics, 2010, Vol. 19, No. 4Figure 2. Common SNP markers in LEP are associated with IL-6 and leptin expression. (A) Single marker allelic association results for LEP gene locus with
IL-6 or leptin expression plotted as 2log10(P) values by genomic coordinate. With reference to rs4731427, SNPs with MAF greater than 5% and r
2 , 0.2 are
shown as white squares, 0.2–0.5 (yellow) and 0.5–0.8 (orange). LEP gene structure and genotyped SNPs are shown below. Estimated recombination rates are
shown from HapMap (using Build 35 coordinates). Gene structure, vertebrate multiz alignment and conservation track (17 species) (49) and genotyped SNP
locations adapted from screenshot of the UCSC Genome Browser (Human March 2006 Assembly). (B) Manhattan plot showing strength of association from
PLINK analysis plotted as 2log10(P) values by chromosome for leptin expression.
Human Molecular Genetics, 2010, Vol. 19, No. 4 723haplotype reﬁnes the observed association with rs4731427 and
suggests the functional variant may be localized within this
haplotype.
Our data are supported by the previous independent reports
of associations with leptin expression and obesity for a
common non-coding SNP 2.5 kb upstream of LEP,
rs7799039 (23–26). We observed a signiﬁcant association
with rs10487506, an SNP marker in complete LD with
rs7799039 (Supplementary Material, Fig. S3); this SNP also
shows a weak association with IL-6 expression at 6 h after
Figure 3. Association of IL-6 and leptin expression with rs4731427. Scatter plots are shown for IL-6 expression at either the (A) RNA (relative to actin and plotted
on log scale with median value indicated) or (B) protein level (with mean value and 95% conﬁdence intervals shown) together with data for (C) LEP RNA.
724 Human Molecular Genetics, 2010, Vol. 19, No. 4LPS induction (2 ng/ml) (unadjusted P-value 0.03). However,
our dense SNP genotyping at the LEP gene locus resolves the
likely underlying functional haplotype with much greater pre-
cision and suggests that the functional cis-acting variant is not
rs7799039, but carried on the LEP4 haplotype.
Signals of association with IL-6 expression at ALOX15
and CAPNS1
We found two SNP markers in complete LD (rs11568131 and
rs11078527) (c. 287C.T and c.808-94C.T) located in the
30-UTR and sixth intron of ALOX15 which showed a robust
signal of association with IL-6 expression at both the RNA
and protein level, and with different doses of LPS (Fig. 5, Sup-
plementary Material, Figs S1 and S3). LD was relatively low
and haplotypic analysis was not more informative than single
SNP association for IL-6 expression. In our population
sample, possession of one or more copies of the haplotype
carried by the T alleles of rs11568131 and rs11078527 was
associated with a 3-fold higher level of IL6 RNA expression
following 2 ng/ml LPS induction for 6 h (Mann–Whitney
test two-tailed P ¼ 0.0002) and a 1.5- or 1.7-fold higher
level of IL-6 protein expression (following 2 or 20 ng/ml
LPS induction, respectively) (unpaired t-test two-tailed P ¼
0.0007 and P ¼ 0.0008) (Supplementary Material, Fig. S3).
The SNPs are present in non-conserved regions of DNA not
associated with regulatory potential based on seven species
alignments (27) or any predicted transcription factor binding
site (28). We note that the associated SNPs occur twice as fre-
quently among individuals of Caucasian geographic ancestry
(MAF in CEU 0.183) compared with individuals of African
or Asian ancestry (29).
We also observed a strong signal of association with IL-6
expression for a common SNP marker at CAPNS1, rs17882574
(c.721 þ 391A.G) (Fig. 5, Supplementary Material, Figs S1
andS3).ThislocusalsohaslowLDwithinindividualsofCauca-
sianancestry.IndividualswithoneormorecopiesoftheminorG
allele had a 2.8-fold increased IL6 RNA expression following
2 ng/ml LPS induction for 6 h (Mann–Whitney test two-tailed
P ¼ 0.03); and a 1.8- or 2.0-fold increased IL-6 protein
expression(2or20 ng/mlLPSinduction,respectively)(unpaired
t-test P , 0.0001 for either phenotype) (Supplementary
Material, Fig. S3). The SNP marker rs17882574 lies within the
middle of the ninth intron of CAPNS1 in a non-conserved
region of DNA not associated with regulatory potential, or pre-
dictedtranscriptionfactorbinding.Nodataispublicallyavailable
from HapMap or other resources comparing allele frequencies
for this SNP between populations.
Finally, among all the IL-6 phenotypes studied, no strong
signal of association was found with IL-6 production at the
IL6 locus itself, including previously reported promoter
SNPs IL6-174C/G (rs1800795), IL6-572C/G (rs1800796)
Figure 4. Haplotypic analysis of LEP. For volunteers of Caucasian ancestry, genotyped SNPs of greater than 5% MAF were used to infer the underlying hap-
lotypic structure using Haploview. Haplotype blocks shown deﬁned based on (A) conﬁdence intervals (47) or (B) solid spine of LD. The Haploview plot for D0
shows the following: white and blue squares have a LOD score of less than 2 (indicating lower conﬁdence) with the white having D0 , 1 and blue having a D0 ¼
1. Those squares that are shades of pink to red have a LOD score greater than 2 and have D0 , 1, while the red squares represent D0 ¼ 1. (C) Haplotypic associ-
ation for expression phenotypes shown based on six inferred haplotypes at LEP locus.
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troversial and a number of other studies ﬁnd no evidence of
association (5–7,30–33) (Supplementary Material, Fig. S4).
We successfully genotyped a total of 40 SNPs across a
20 kb region spanning IL6 at chromosome 7p15.3, of which
22 were informative with an MAF greater than 5%.
Several genetic factors contribute to variation
in IL-6 expression
Our data set from healthy volunteers leads to the hypothesis
that genetic variation at LEP, ALOX15 and CAPNS1 is signiﬁ-
cantly associated with observed variation in induced IL-6
expression between individuals. We used a linear regression
model to assess this relationship further. We found that the
associated common SNP markers at each of these genes
(rs4731427, rs11568131 and rs17882574, respectively) were
each signiﬁcant and independent predictors of IL-6 protein
expression, together explaining approximately one-third of
observed variation in induced IL-6 protein levels in this data
set (Supplementary Material, Table S2). For IL6 RNA,
rs17882574 was not a signiﬁcant predictor and the ﬁnal
model only included rs4731427 and rs11568131, explaining
23% of observed variance in IL6 RNA expression. The LEP
SNP rs4731427 was signiﬁcant for all the IL-6 phenotypes
and when analysed in a linear regression model for leptin
RNA explained 17% of observed variance in leptin expression
(Supplementary Material, Table S2).
Evidence of association with other cytokines involved
in the inﬂammatory response
These data identify a number of candidate variants associated
with differential expression of IL-6 at the transcript and
protein level. For LEP, we noted evidence of cis-acting regu-
latory variants modulating leptin expression and in turn IL-6
levels, while for genetic variation at ALOX15 and CAPNS1
the basis of our observed association with IL-6 expression is
unknown. The evidence of a pro-inﬂammatory role for the
products of 12/15-lipoxygenase (12/15 LOX) encoded by
ALOX15 in stimulating cytokines such as IL-6 (34–36), and
of calpain (encoded in part by CAPNS1) in regulating
NF-kB signalling through cleavage of IkB (37), would
suggest that the associated polymorphisms in these genes
might modulate the expression of cytokines other than IL-6.
To investigate this, we assayed LPS induced expression of a
panel of cytokines whose expression remained elevated at
6 h following LPS stimulation (the time RNA was harvested)
and looked for evidence of association with the IL-6-
associated SNPs rs11568131, rs17882574 and rs4731427.
Transcript abundance was assayed for IL-1beta (IL-1B),
IL-10, IL-12 subunit alpha (IL-12A) and beta (IL12-B) and
IL-23. Tumour necrosis factor (TNF) was also assayed but
as transcript levels virtually normalise by 6 h (data not
shown), ELISAs of supernatant were performed to quantify
TNF protein abundance. This analysis showed a signiﬁcant
association between the rs11568131 polymorphism in
ALOX15, previously associated with increased IL-6
Figure 5. Association with IL-6 and SNP markers at ALOX15 and CAPNS1. Single marker allelic association results for IL-6 eQTL and pQTLs are shown plotted
as 2log10(P) versus genomic coordinate for (A) ALOX15 gene region and (B) CAPNS1 gene region. For each of the top associated SNPs in the two gene loci
(plotted with blue squares), SNPs with MAF greater than 5% and r
2 , 0.2 are shown as white squares, 0.2–0.5 (yellow) and .0.8 (red). In total, 45 SNPs over a
20 kb region spanning ALOX15 and 47 SNPs over a 50 kb region at CAPNS1 were genotyped.
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uals with a copy of the T allele had 1.4-fold higher levels of
IL1B transcript compared with those without (Mann–Witney
test two-tailed P ¼ 0.009) and 1.5-fold higher levels of TNF
protein (P ¼ 0.005 unpaired t-test, two-tailed) (Supplementary
Material, Fig. S5). No signiﬁcant association was noted for the
other cytokines assayed with this SNP or the two
IL-6-associated SNPs at CAPNS1 and LEP, respectively.
DISCUSSION
IL-6 is a potent pro-inﬂammatory cytokine and tight regulation
of its synthesis and release is critical to its role in modulating
acute and chronic inﬂammation. For cytokines such as IL-6,
the resolution of functionally important genetic variation
requires analysis in a relevant cell type following induction
of gene expression with a physiologically appropriate stimu-
lus. Here we report a signiﬁcant association between levels
of IL-6 production on LPS stimulation of primary human
PBMCs and possession of common SNP markers at the
ALOX15, CAPNS1 and LEP gene loci which together
explained up to one-third of the variance in induced IL-6
expression in our cohort. Given the sample size, it is possible
that the observed effect sizes may be an overestimate, as pre-
viously noted in QTL mapping studies in which the proportion
of phenotypic variance explained for correctly identiﬁed loci
was dependent on the number of progeny examined (the
so-called Beavis effect) (38). However, our data identiﬁes
complex cis- and trans-acting variants modulating IL-6
expression which are of high biological plausibility, and for
ALOX15 provides evidence of association with the expression
of other cytokines involved in the acute inﬂammatory
response.
For LEP, we note that irrespective of genotype, the basal
expression of leptin strongly correlates with subsequent
LPS-induced IL-6 levels. Furthermore, we ﬁnd that LEP
SNPs showing trans association with IL-6 expression are
themselves highly associated with increased basal expression
of leptin, supporting a mechanism whereby relative expression
of leptin can inﬂuence subsequent induced IL-6 responses.
Genetic factors play a signiﬁcant role in determining circulat-
ing levels of leptin, accounting for 34% of the observed var-
iance in women and 45% in men among adult Finnish twins
(39). Our dense SNP typing at LEP ﬁne maps a previously
reported SNP (rs7799039, ‘22548G/A’) (23,24) association
with leptin expression to a speciﬁc haplotype and has
important potential implications for our understanding of the
pathophysiology associated with IL-6, notably in
inﬂammation-related disease. The observed differences at a
protein level in IL-6 expression of 1.7- to 2-fold associating
with LEP genotype may be clinically highly signiﬁcant,
emphasising the potential disease relevance of these data.
Although leptin was initially identiﬁed for its role in regu-
lating appetite and metabolism, it also plays an important
immunomodulatory role in both infectious and inﬂammatory
states with increased leptin expression in response to LPS
described (40,41). Leptin pre-treatment has been shown to
augment LPS-induced IL-6 production, while obese/obese
mice with deﬁcient leptin receptor signalling have signiﬁ-
cantly reduced LPS-induced IL-6 production (20,21). Simi-
larly, individuals with severe lipodystrophy exhibit reduced
blood leptin levels and subnormal LPS responses with
altered lymphocyte subsets; both of which can be corrected
by exogenous leptin replacement (42). In microglia leptin
leads to dose- and time-dependent increases in IL-6 production
with enhanced recruitment of NF-kB, the coactivator p300 and
histone acetylation at the IL6 promoter (22).
ALOX15 is implicated in multiple pathologies including
atherosclerosis, diabetes and myeloproliferative disease (43).
The gene is highly expressed in monocytes and macrophages
and encodes 12/15 LOX, an enzyme regulating fatty acid
and lipoprotein metabolism and leukotriene synthesis.
Recent biological evidence supports a link with expression
of inﬂammatory cytokines including IL-6. Activity of 12/15
LOX leads to the generation of unstable lipid products from
arachidonate that stimulate expression of IL-6 and TNF in
mouse adipocytes (35) and macrophages (34), while targeting
12/15 LOX with siRNAs results in reduced expression of
inﬂammatory genes including IL-6 (44). Moreover, 12/15
LOX knock out mice show reduced expression of cytokines
including TNF by peritoneal macrophages in response to bac-
terial infection, suggesting a key role for this enzyme in the
acute inﬂammatory response (36). These mice also fail to
show high fat diet induced IL-1B, IL-6 and TNF expression
in adipocytes (45), implicating a role for 12/15 LOX in the
chronic inﬂammatory metabolic syndrome.
Our data demonstrates that speciﬁc genetic variants in
ALOX15 not only affect IL-6 expression, but also inﬂuence
the expression of IL-1B and TNF, cytokines both intimately
associated with the acute inﬂammatory response. The mechan-
ism for this remains unclear but does not appear to be through
a non-speciﬁc pro-inﬂammatory effect as evidenced by the
absence of association with expression of the other cytokines
assayed including IL-10 and IL-12. Speciﬁcity is also indi-
cated by the absence of association of TNF and IL-1B
expression with the LEP and CAPNS1 SNPs, which suggests
that the effect of ALOX15 activity on the induction of these
cytokines is not through an effect on IL-6. Likewise, the
association of leptin and IL-6 adds another tier to the wealth
of data implicating a tight relationship between these cyto-
kines, in particular highlighting how basal leptin may modu-
late subsequent IL-6 levels.
Additional work is required to conﬁrm and ﬁne map our
common SNP marker associations with IL-6, to deﬁne the cau-
sative functional variants and their role in the broader inﬂam-
matory cascade. Our data set provides proof of concept for a
combined eQTL/pQTL approach utilizing a carefully pheno-
typed cohort which includes different dose effects on induction
of gene expression, allowing for replication of association
within the cohort and resolution of SNP markers and haplotypes
consistently associated with differential gene expression.
MATERIALS AND METHODS
Ethics statement
This study was approved by the Oxfordshire Research Ethics
Committee (REC reference 06/Q1605/55). All volunteers pro-
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and subsequent analysis.
Study volunteers
Healthy volunteers from the Oxfordshire area were recruited
and 50 ml of blood was venesected into EDTA-containing
vacuutainer tubes. Sex, age and self-reported ethnicity were
recorded and the samples anonymized. The median age of
the 96 volunteers was 30 years (range 21–64 years); 59
were female; 82 were of European Caucasian origin while
the remainder were of Asian descent (10 Indian and 4
Chinese). Self-reported ethnicity was conﬁrmed with reference
to SNP data using principal components analysis from the
HapMap. A distance matrix was generated from the whole
genome autosomal genotyping data using an agglomerative
clustering algorithm. The subjects were observed to cluster
in three groups corresponding to the reported ethnicities.
Although a distinct structure was observed with the entire
data set, it did not inﬂuence the results. Ethnicity was not sig-
niﬁcant in both regression models and in within-cluster permu-
tations.
PBMC puriﬁcation and ex vivo stimulation assays
Volunteers were venesected in the morning and PBMC puri-
ﬁed using a Ficoll (Sigma-Aldrich) gradient within 2 h of
sample collection. In order to minimize differential expression
patterns due to circadian expression oscillations all blood
samples were collected at the same time of day and cultured
and processed in batches. Using a pasteur pipette, the PBMC
layer was gently aspirated and washed twice in excess
Hanks buffered saline solution buffer (without Ca
2þ or
Mg
2þ) and then with culture media. Cells were counted with
a haemocytometer using trypan blue staining and resuspended
at 2.5   10
6 cells per ml in RPMI 1640 growth medium
(Sigma) supplemented with L-glutamine (2 mM), penicillin/
streptomycin (100 U/ml penicillin, 0.1 mg/ml streptomycin)
and 10% v/v heat-inactivated Gold standard fetal calf serum
prior to being aliquoted into 14 ml polystyrene tubes
(Becton Dickinson) tubes at 1 ml per tube. Three biological
replicate assays per condition were set up for each volunteer.
After incubation overnight at 378C in 5% humidiﬁed CO2,
cells were washed once with fresh media and then resuspended
in fresh media alone (untreated) or fresh media with LPS at
either 2 or 20 ng/ml (ﬁnal concentration). LPS was purchased
from Sigma (L-4391) lot 114K4133. Cells were incubated for
a further 6 h prior to the separation of cells from supernatant
by centrifugation. Supernatants for IL-6 ELISA were stored
at 2808C prior to quantiﬁcation and cell pellets were resus-
pended in RLT buffer (Qiagen) supplemented with beta-
mercaptoethanol and stored at 2808C for subsequent RNA
extraction.
ELISAs
ELISAs were performed in 96-well plates following the man-
ufacturer’s instructions using IL-6 and TNF Duoset kits (DY
206, DY210 R&D Systems), with protein concentrations esti-
mated at 450 nm from a standard calibration curve included on
each plate. All samples were analysed in duplicate.
RNA extraction, cDNA synthesis and quantitative PCR
Total RNA was prepared using the RNAeasy Mini kit
(Qiagen) following the manufacturer’s instructions with
inclusion of a DNase I digestion step on the RNAeasy minicol-
umn. Following quantiﬁcation, cDNA was prepared using
SuperScript III (Invitrogen) using random primers and follow-
ing the manufacturer’s instructions which included digestion
with RNase H (Invitrogen) following cDNA synthesis.
Control RT reactions omitting the reverse transcriptase were
included for each sample. Quantitative PCR was performed
using SYBR Green Supermix (BioRad) on an iQ Cycler
(BioRad). PCR efﬁciency was determined and melt curve
analysis performed for gene speciﬁc primer sets (ACTB: fwd
CCAGCCTTCCTTCCTGGGC rev TGTGTTGGCGTACA
GGTCTTTGC; IL6: fwd GCTATGAACTCCTTCTCCA
CAAGC, rev CCCTACATCTTTGGAATCTTCTCC; IL10:
fwd GGTGAAGAATGCCTTTAATAAGCTCC, rev TTTCG
TATCTTCATTGTCATGTAGGC; IL12A: fwd CAGCAACA
TGCTCCAGAAGGC, rev TAAATACTACTAAGGCACA
GGGCCATC; IL12B: fwd AGTGTCAAAAGCAGCAGA
GGCTC, rev TTGGGTGGGTCAGGTTTGATG; IL1B: fwd
ATGGCCCTAAACAGATGAAGTGC, rev GAAGGGAAA
GAAGGTGCTCAGG; IL23: fwd CACTAGTGGGACACA
TGGATCTAAG, rev GATCCTTTGCAAGCAGAACTGA
C). Relative gene transcript levels were determined by the
DDCt method. Leptin was quantiﬁed using the ABI ‘assay
on demand’ Hs00174877m1 probe set (Applied Biosystems).
Genechip hybridization platform (Illumina BeadArray)
Genomic DNA was prepared for each of the healthy volun-
teers and quantiﬁed using the Nanodrop technology. Genotyp-
ing was performed using the humanCVD bead array chip
(Illumina) following manufacturers recommendations as pre-
viously described (17).
LD and haplotype analysis
LD estimates and haplotypes were computed using the
HaploView 3.3.2 program (46). For volunteers of Caucasian
ancestry, genotyped SNPs of greater than 5% MAF were
used to infer the underlying haplotypic structure with LD
blocks predicted by the Conﬁdence Intervals algorithm as
previously described (47). An accelerated expectation-
maximization algorithm was used to create highly accurate
population frequency estimates of the phased haplotypes
based on maximum likelihood as determined from unphased
input (46).
Statistical analysis
PLINK was the primary software utilized for analysis of the
data sets within this study (48). Statistics were veriﬁed using
SPSS, R package and SNPTest, and concordant statistical
results were obtained. Standard QC measures included exclu-
sion criteria of maximum per-person missing (MIND . 0.1),
728 Human Molecular Genetics, 2010, Vol. 19, No. 4maximum per-SNP missing (GENO . 0.1) and MAF , 0.01.
After frequency and genotyping pruning, and removing
individuals with low genotyping success rates, the total
genotyping rate in the remaining individuals was more than
98.8% for the Illumina humanCVD beadchip. PLINK was
used to perform quantitative trait analysis which generates a
P-value using the Wald test. For each SNP, PLINK generates
a phenotypic mean for the three genotypic states and compares
these means using the Wald test statistic to generate a P-value.
The Wald test is useful especially in this instance, since it does
not require that the data ﬁt a normal distribution. Covariates
age, ethnicity and sex were included as additional terms in
PLINK analysis to further interrogate observed associations.
Non-parametric statistics and log transformation were
applied where data were not normally distributed, otherwise
unpaired t-tests were used for analysis of expression data for
speciﬁc SNPs, data passing tests of normality. Permutation
analysis was performed using a label-swapping procedure
which swaps phenotypes while retaining the genotype
linkage structure. An adaptive algorithm was used which
speeds computations by dropping SNPs less likely to be
signiﬁcant in each iteration. Analysis was performed with
one million permutations using a within-cluster algorithm
which swaps labels within each population cluster. The
analysis was repeated without any restrictions. The empirical
P-value is robust with respect to normality of phenotype
and multiple testing issues. Haplotypic association analysis
was also performed using the haplotypes deﬁned as described
earlier. A linear regression model was used to estimate
the contribution of the most strongly associated SNPs to
IL-6 expression. Potential confounding factors (age, sex and
ethnicity) were then added to the core model. Factors which
did not contribute signiﬁcantly to the ﬁt of the model on
likelihood ratio testing (P, 0.05) were excluded. Linear
regression analysis was carried out using STATA v10
software.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
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